Anticoagulation: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett (Started external links) |
||
| Line 7: | Line 7: | ||
==See also== | ==See also== | ||
* [[Anticoagulant]] | * [[Anticoagulant]] | ||
==External links== | |||
[http://www.chestjournal.org/content/vol126/3_suppl/ The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines] | |||
[[Category:CZ Live]] [[Category:Health Sciences Workgroup]] | [[Category:CZ Live]] [[Category:Health Sciences Workgroup]] | ||
Revision as of 15:55, 20 December 2007
Adverse effects
Patients aged 80 years or more may be especially susceptible to bleeding complications with a rate of 13 bleeds per 100 person-years.[1]
References
- ↑ Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007). "Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation". Circulation 115 (21): 2689-96. DOI:10.1161/CIRCULATIONAHA.106.653048. PMID 17515465. Research Blogging. PMID 17515465
See also
External links
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines